EQS-News: ABIVAX / Key word: Miscellaneous
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
22.01.2024 / 08:30 CET/CEST
The.
Organovo To Present FXR314 IBD 3D Model Findings At Upcoming Crohn'S And Colitis Congress menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative
Celltrion Healthcare, Celltrion Group's sales arm, announced Thursday that the company’s autoimmune disease treatment Zymfentra will make its debut in the US market on Feb. 29 next year. Zymfentra, which is also known as Remsima SC, is a subcutaneous injection formulation of Celltrion's infliximab Remsima, a treatment for patients with rheumatoid arthritis, Crohn’s disease, ulcerative colitis, a.